* Tovaxin has yielded a DEMONSTRATED Annual Relapse Rate of .20. THIS IS IN THE MOST FAVORABLE RANGE of ANY MS drug CURRENTLY SOLD ON THE $1B MS MARKET. That's right- Tovaxin scores a better relapse rate score than ALMOST ALL of the MS drugs which make up the current $1 billion MS market.
* Unlike many other drugs approved and currently marketed, THERE HAS NOT BEEN ONE ADVERSE EVENT RELATED TO TREATMENT ON TOVAXIN- NOT ONE. If you don't know of someone with MS who has been treated, this is SIGNIFICANT.
* 83% of Tovaxin patients were RELAPSE FREE at the end of 1 year on Tovaxin. 73% of Tovaxin patients were STABLE OR IMPROVED when measured for disability, and nearly one in 5 had A FULL POINT IMPROVEMENT in the EDSS scale used to measure disability.
* These are SOME of the excellent points that as an OPXA investor I expect to be more fully detailed in the months to come.
OPXA also has a fully detailed investor section at www.opexatherapeutics.com for further research.
Market Data 
Markets 
AI
